MahilSK.DandN.MasonKJet al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71.doi:10.1016/j.jaci.2020.10.00733075408
2.
DongJ.GoldenbergG. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017;99(2):123-127.28319618
3.
TangH-J.LaiC-C.ChaoC-M. Changing epidemiology of respiratory tract infection during COVID-19 pandemic. Antibiotics. 2022;11(3):315.doi:10.3390/antibiotics1103031535326778
4.
GordonKB.LebwohlM.PappKAet al. Long-Term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466-475.doi:10.1111/bjd.2081834652810
5.
JonesME.KohnAH.PouraliSPet al. The use of biologics during the COVID-19 pandemic. Dermatol Clin. 2021;39(4):545-553.doi:10.1016/j.det.2021.05.01034556244
